Literature DB >> 8282961

Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism.

E Faloia1, S Filipponi, V Mancini, P Morosini, R De Pirro.   

Abstract

Six women with acne and six women with hirsutism were treated with the GnRH analog [D-Ser(Bu(t))6] LHRH-(1-9)ethylamide (Buserelin) for 6 months (nasal spray, 1,200 micrograms/day) to suppress ovarian steroidogenesis. All women were eumenorrheic and did not demonstrate any adrenal or ovarian dysfunction. During treatment, ovarian steroids, LH and FSH decreased, while DHEA-S showed minor modifications; the clinical score for both acne and hirsutism showed a significant reduction. Moreover, acne and hirsutism were still well controlled 6 months after therapy. Gonadal function resumed in all patients after discontinuation of therapy. Three patients suffered from hot flashes from the 4th month. These data demonstrate that suppression of ovarian steroid secretion might be an efficient treatment in women suffering from acne or idiopathic hirsutism, indicating that ovarian steroids may have a key-role in the pathogenesis of these conditions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8282961     DOI: 10.1007/BF03348907

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  11 in total

1.  Clinical assessment of body hair growth in women.

Authors:  D FERRIMAN; J D GALLWEY
Journal:  J Clin Endocrinol Metab       Date:  1961-11       Impact factor: 5.958

Review 2.  Gonadotropin-releasing hormone and its analogues.

Authors:  P M Conn; W F Crowley
Journal:  N Engl J Med       Date:  1991-01-10       Impact factor: 91.245

3.  Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?

Authors:  B J Riis; C Christiansen; J S Johansen; J Jacobson
Journal:  J Clin Endocrinol Metab       Date:  1990-04       Impact factor: 5.958

4.  Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women.

Authors:  W H Matta; R W Shaw; R Hesp; D Katz
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-13

5.  The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism.

Authors:  J S Johansen; B J Riis; C Hassager; M Moen; J Jacobson; C Christiansen
Journal:  J Clin Endocrinol Metab       Date:  1988-10       Impact factor: 5.958

Review 6.  Female hirsutism: pathophysiological considerations and therapeutic implications.

Authors:  P Biffignandi; C Massucchetti; G M Molinatti
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

7.  Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.

Authors:  R S Rittmaster; D L Thompson
Journal:  J Clin Endocrinol Metab       Date:  1990-04       Impact factor: 5.958

8.  Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial.

Authors:  E S Surrey; H L Judd
Journal:  J Clin Endocrinol Metab       Date:  1992-08       Impact factor: 5.958

9.  Plasma androgens in women with acne vulgaris.

Authors:  A W Lucky; J McGuire; R L Rosenfield; P A Lucky; B H Rich
Journal:  J Invest Dermatol       Date:  1983-07       Impact factor: 8.551

10.  Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).

Authors:  J L Andreyko; S E Monroe; R B Jaffe
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

View more
  8 in total

Review 1.  Hirsutism: evaluation and management.

Authors:  R E Watson; R Bouknight; P C Alguire
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

2.  Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass.

Authors:  G Lupoli; C Di Carlo; V Nuzzo; G Vitale; D Russo; S Palomba; C Nappi
Journal:  J Endocrinol Invest       Date:  1997-09       Impact factor: 4.256

3.  Effect of finasteride in idiopathic hirsutism.

Authors:  E Faloia; S Filipponi; V Mancini; S Di Marco; F Mantero
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

Review 4.  Acne and the Lesbian, Gay, Bisexual, or Transgender Teenager.

Authors:  Laura Ragmanauskaite; Benjamin Kahn; BaoChau Ly; Howa Yeung
Journal:  Dermatol Clin       Date:  2019-11-26       Impact factor: 3.478

5.  Profiling and hormonal therapy for acne in women.

Authors:  Sangita Ghosh; Soumik Chaudhuri; Vijay Kumar Jain; Kamal Aggarwal
Journal:  Indian J Dermatol       Date:  2014-03       Impact factor: 1.494

Review 6.  Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Authors:  M Filicori
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

Review 7.  Managing Dermatologic Effects of Gender-Affirming Therapy in Transgender Adolescents.

Authors:  Christina Huang; Sarah Gold; Rakan Radi; Seth Amos; Howa Yeung
Journal:  Adolesc Health Med Ther       Date:  2022-10-07

Review 8.  Hormonal treatment of acne vulgaris: an update.

Authors:  Mohamed L Elsaie
Journal:  Clin Cosmet Investig Dermatol       Date:  2016-09-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.